

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/960,652	09/960,652 ' 09/24/2001		Claudio De Simone	2818-58	5995
23117	7590	02/27/2004		EXAMINER	
NIXON & VANDERHYE, PC				AFREMOVA, VERA	
8TH FLOOR				ART UNIT	PAPER NUMBER
ARLINGTON, VA 22201-4714				1651	

DATE MAILED: 02/27/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Advisory Action	09/960,652	DE SIMONE, CLAUDIO					
Advisory Notion	Examiner	Art Unit					
	Vera Afremova	1651					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 04 December 2003 FAILS TO PLAC Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	ation. A proper reply to a					
PERIOD FOR RE	PLY [check either a) or b)]						
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the content o	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CFI of extension and the corresponding amount the shortened statutory period for reply	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or					
(2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 C		ling date of the final rejection, even if					
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.							
2. The proposed amendment(s) will not be entered be	ecause:						
(a) Method they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) ⊠ they raise the issue of new matter (see Note below);							
(c) they are not deemed to place the application ir issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the					
(d) they present additional claims without canceling	ng a corresponding number of fi	nally rejected claims.					
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following reject	ion(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment					
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: Sec		dered but does NOT place the					
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly					
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	• • •						
The status of the claim(s) is (or will be) as follows:	· · · · · · · · · · · · · · · · · · ·						
Claim(s) allowed: <u>none</u> .							
Claim(s) objected to: <u>none</u> .							
Claim(s) rejected: <u>35-43</u> .							
Claim(s) withdrawn from consideration: none.							
8. The drawing correction filed on is a) appr	oved or b) disapproved by t	he Examiner.					
9. Note the attached Information Disclosure Statemer	nt(s)(PTO-1449) Paper No(s)						
10. Other:		V. Dpumou					
		VERA AFREMOVA PH.D. PATENT EXAMINER					

Continuation Sheet (PTOL-303)

Continuation of 2. NOTE: new issues are related to the newly inserted limitation such as "enzymatically active extracts" of strain CD2 that require new considerations/searches including possible double patenting issues. The issue of new matter might also exists as directed to the use and/or administration of enzymatically active alkaline spingomyelinase of the strain CD2.

Continuation of 5. does NOT place the application in condition for allowance because: arguments are not directed solely to the issues raised in the final rejection.